Pharma: Other News To Note
Wednesday, September 4, 2013
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, entered a research service agreement with diagnostics firm Diaxonhit, of Paris, for the discovery and characterization of splice variants that have the potential to be therapeutic targets for oncology. With the agreement, Boehringer secures an option to acquire the rights to research, develop and commercialize any targets identified using Diaxonhit’s Splicearray discovery platform.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.